ARQ-197 enhances the antitumor effect of sorafenib in hepatocellular carcinoma cells via decelerating its intracellular clearance

BACKGROUND: Hepatocellular carcinoma (HCC) is one of the heaviest malignant burdens in China. Molecular targeting agent, sorafenib, is the main therapeutic option for antitumor therapy of advanced HCC, but it is currently too expensive for the public and its therapeutic effect does not satisfy initi...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Xudong, Chen, Hebing, Huang, Xin, Li, Hao, Liu, Zhen, Bo, Xiaochen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6396672/
https://www.ncbi.nlm.nih.gov/pubmed/30881018
http://dx.doi.org/10.2147/OTT.S196713

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6396672/
https://www.ncbi.nlm.nih.gov/pubmed/30881018
http://dx.doi.org/10.2147/OTT.S196713

Ejemplares similares